Physician profile
Mary Michael
NPI 1881213650
$4,435.57
in general payments reported to CMS, 2019-2025
28 companies · $1,275 in 2025
The $1,275 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $110 · 2022: $702 · 2023: $1,021 · 2024: $1,327 · 2025: $1,275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,623.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $685.85 | 2023-2025 | Sotyktu |
| Abbvie INC. | $385.78 | 2023-2025 | |
| Kerecis Limited | $290.50 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
| Galderma Laboratories, L.P. | $290.22 | 2023-2025 | Twyneo, Aklief, Oracea |
| Janssen Biotech, INC. | $265.59 | 2022-2024 | Tremfya, Simponi, Stelara |
| Incyte Corporation | $251.63 | 2021-2024 | Opzelura |
| Ucb, INC. | $248.35 | 2022-2025 | Bimzelx |
| Amgen INC. | $241.83 | 2022 | |
| Arcutis Biotherapeutics, INC. | $209.84 | 2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $205.69 | 2021-2024 | Targretin, Siliq, Jublia |
| Genzyme Corporation | $178.15 | 2025 | |
| Organogenesis INC. | $165.76 | 2024-2025 | Cygnus Dual |
| Sun Pharmaceutical Industries INC. | $147.64 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $138.30 | 2023-2025 | Dupixent |
| Genentech USA, INC. | $120.47 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Krystal Biotech INC | $100.69 | 2024 | Vyjuvek |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.82 | 2022-2024 | Spevigo |
| Werfen USA LLC | $87.22 | 2023 | |
| Novartis Pharmaceuticals Corporation | $68.11 | 2023-2025 | |
| Pfizer INC. | $57.00 | 2025 | |
| Leo Pharma INC. | $43.00 | 2025 | Spevigo, Anzupgo |
| Biofrontera INC. | $37.98 | 2022-2025 | Ameluz |
| Ani Pharmaceuticals, INC. | $23.25 | 2025 | Veregen |
| Kyowa Kirin, INC. | $22.55 | 2022 | |
| Lilly USA, LLC | $20.44 | 2022 | |
| Genentech, INC. | $18.32 | 2023 | Erivedge |
| Helsinn Therapeutics (U.S.), INC. | $17.81 | 2023 | Valchlor |
| Strata Skin Sciences, INC. | $16.78 | 2025 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Michael listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.